Valuation
- Market cap
- 115,827,000
- Revenue TTM
- $10,000
- Net income TTM
- $-32,150,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -321,500.02%
- Debt to equity
- 0.00
Trading
- Volume
- 278,200
- Avg volume
- 299,130
- Day's range
- $2.52 – $2.59
- Shares out
- 45,245,000
- Stochastic %K
- 65%
- Beta
- 0.59
- Analysts
- Strong Sell
- Price target
- $18.83
Company profile
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discover...
Show more
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 805 267 9889
- Website
- https://www.genelux.com
- Address
- 2625 Townsgate Road, Suite 230, Westlake Village, United States
Latest news
No headlines yet.
